Abstract
The ribosomal L3 protein was identified as a novel target in linezolid (LZD)-resistant Mycobacterium tuberculosis strains. Next-generation sequencing confirmed rplC T460C as the sole mutation in an LZD-resistant M. tuberculosis H37Rv strain selected in vitro. Sequencing analysis revealed the rplC T460C mutation in eight further LZD-resistant isolates (three in vitro-selected mutants and five patient isolates, including isolates from three different patients that developed LZD resistance during treatment) but in none of the susceptible control strains (n = 84).
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetamides / pharmacology*
-
Antitubercular Agents / pharmacology*
-
DNA, Bacterial / genetics
-
Drug Resistance, Bacterial / genetics
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Linezolid
-
Microbial Sensitivity Tests
-
Mutation*
-
Mycobacterium tuberculosis / drug effects
-
Mycobacterium tuberculosis / genetics*
-
Mycobacterium tuberculosis / isolation & purification
-
Oxazolidinones / pharmacology*
-
Ribosomal Protein L3
-
Ribosomal Proteins / genetics*
Substances
-
Acetamides
-
Antitubercular Agents
-
DNA, Bacterial
-
Oxazolidinones
-
Ribosomal Protein L3
-
Ribosomal Proteins
-
Linezolid